Charles River Laboratories International, Inc. (New York Stock Exchange:CRL)
| Market Cap | $15.06B+84.4% |
| Revenue (ttm) | $3.98B-1.2% |
| Net Income | $40.19M+148.1% |
| EPS | $0.91+158.3% |
| Shares Out | 47.92M |
| PE Ratio | 308.16 |
| Forward PE | 24.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,154,114 |
| Open | $324.71 |
| Previous Close | $327.93 |
| Day's Range | $310.52 - $326.62 |
| 52-Week Range | $146.20 - $379.63 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | $313.67(-0.21%) |
| Earnings Date | Feb 17, 2027 |
About CRL
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories International, Inc. Stock Analysis — InsiderScore
Charles River Laboratories International, Inc. scored higher than 23% of companies evaluated by InsiderBuying, and ranked 43rd out of 56 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Charles River Laboratories International, Inc. bought $3.0K of stock across 1 purchase in the last 90 days, the largest of them $3.0K.
The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
10 firms rating CRL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 17, 2027Earnings report
$CRL stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CRL by members of U.S. Congress
| Julie JohnsonHouse / D | Purchase$1.00K – $15.00K | Jan 15, 2025 |
| Donna ShalalaHouse | Sale$1.00K – $15.00K | Jun 24, 2019 |
Recently reported changes in CRL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CRL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CRL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CRL Revenue by Segment or Geography
| DSA | $596.32M | 60.68% |
| RMS | $207.53M | 21.12% |
| Manufacturing | $178.88M | 18.20% |
As of: Q3 2026 (Sep 26, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CRL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CRL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CRL
| VOOVanguard S&P 500 ETF | $456.04M |
| VTIVanguard Morningstar Total Stock Market ETF | $430.21M |
| VBVanguard Morningstar Small-Cap ETF | $384.65M |
| VBRVanguard Morningstar Small-Cap Value ETF | $250.05M |
| RSPInvesco S&P 500 Equal Weight ETF | $240.93M |
| IVViShares Core S&P 500 ETF | $210.94M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CRL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong YoY stock performance, analyst price target maintained, geographic expansion, and business partnerships indicate positive momentum despite valuation questions.
Recent Insider Activity
Insider Score Trend Over Time
+55.6 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| OAKL | Oakmark U.S. Concentrated ETF | 4.28% |
| FCUS | Pinnacle Focused Opportunities ETF | 3.38% |
| EPSB | Harbor SMID Cap Core ETF (EPSB) | 3.28% |
| SAMM | Strategas Macro Momentum ETF | 3.20% |
| FMTM | MarketDesk Focused U.S. Momentum ETF | 3.16% |
| IVDG | Invesco Focused Discovery Growth ETF | 2.88% |
| EPAI | Harbor ETF Trust - Harbor AI Inflection Strategy ETF | 2.52% |
| EPSV | Harbor SMID Cap Value ETF (EPSV) | 2.48% |
| QMOM | Alpha Architect U.S. Quantitative Momentum ETF | 2.43% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 2.37% |
| EPMV | Harbor Mid Cap Value ETF (EPMV) | 2.17% |
| SAEF | Schwab Ariel ESG ETF | 1.90% |
Weight is the stock’s share of each fund’s holdings.
